Redalyc.RESÚMENES
Total Page:16
File Type:pdf, Size:1020Kb
Journal of Pharmacy & Pharmacognosy Research E-ISSN: 0719-4250 [email protected] Asociación de Académicos de Ciencias Farmacéuticas de Antofagasta Chile RESÚMENES Journal of Pharmacy & Pharmacognosy Research, vol. 2, núm. 1, mayo, 2014, pp. sxi- s357 Asociación de Académicos de Ciencias Farmacéuticas de Antofagasta Antofagasta, Chile Disponible en: http://www.redalyc.org/articulo.oa?id=496050651001 Cómo citar el artículo Número completo Sistema de Información Científica Más información del artículo Red de Revistas Científicas de América Latina, el Caribe, España y Portugal Página de la revista en redalyc.org Proyecto académico sin fines de lucro, desarrollado bajo la iniciativa de acceso abierto © 2014 Journal of Pharmacy & Pharmacognosy Research, 2 (Suppl. 1), S1-S357 ISSN 0719-4250 http://jppres.com/jppres RESÚMENES / ABSTRACTS «LATINFARMA Habana 2013» / «LATINFARMA Havana 2013» _____________________________________ This is an open access article distributed under the terms of a Creative Commons Attribution-Non-Commercial-No Derivative Works 3.0 Unported Licence. (http://creativecommons.org/licenses/by-nc-nd/3.0/ ) which permits to copy, distribute and transmit the work, provided the original work is properly cited. You may not use this work for commercial purposes. You may not alter, transform, or build upon this work. Any of these conditions can be waived if you get permission from the copyright holder. Nothing in this license impairs or restricts the author's moral rights. Este es un artículo de Acceso Libre bajo los términos de una licencia “Creative Commons Atribucion-No Comercial-No trabajos derivados 3.0 Internacional” (http://creativecommons.org/licenses/by-nc- nd/3.0/deed.es) Usted es libre de copiar, distribuir y comunicar públicamente la obra bajo las condiciones siguientes: Reconocimiento. Debe reconocer los créditos de la obra de la manera especificada por el autor o el licenciador (pero no de una manera que sugiera que tiene su apoyo o apoyan el uso que hace de su obra). No comercial. No puede utilizar esta obra para fines comerciales. Sin obras derivadas. No se puede alterar, transformar o generar una obra derivada a partir de esta obra. Al reutilizar o distribuir la obra, tiene que dejar bien claro los términos de la licencia de esta obra. Alguna de estas condiciones puede no aplicarse si se obtiene el permiso del titular de los derechos de autor Nada en esta licencia menoscaba o restringe los derechos morales del autor. LATINFARMA 2013 Índice/Index ÍNDICE / INDEX CONFERENCIAS PLENARIAS INAUGURALES / OPENING PLENARY LECTURES (PL) 1 Lunes, Octubre 21 / Monday, October 21st 1 Martes, Octubre 22 / Tuesday, October 22nd 1 PL 001: BIOLOGICAL AND THERAPEUTIC RELEVANCE OF THE DISCOVERY OF PROSTACYCLIN AND NITRIC OXIDE: Moncada S 1 PL 002: IMMUNOTHERAPY AND COMPLEXITY: OVERCOMING THE BARRIERS FOR THE CONTROL OF ADVANCED CANCER: Lage Dávila A 1 PL 003: TRENDS OF RESEARCH IN THE 21RST CENTURY: Moncada S 1 Taller sobre Inmunofarmacología y Biotecnología. Sesión: Inmunofarmacología / Workshop on Immunopharmacology and Biotechnology. Session; Immunopharmacology 2 CO 001: TOWARDS CLINICAL TRANSLATION OF T-CELL RECEPTOR GENE EDITING TO MEDIATE ADOPTIVE ANTI-TUMOR IMMUNOTHERAPY: Ciceri F et al. 2 CO 002: HUMAN ANTIBODIES REACTIVE TO NEUGCGM3 GANGLIOSIDE HAVE CYTOTOXIC ANTITUMOR PROPERTIES: Rodríguez-Zhurbenko N et al. 2 CO 003: PHARMACOLOGIC INTERVENTION OF CASEIN KINASE 2 (CK2)-MEDIATED PRO-SURVIVAL AND PROLIFERATIVE SIGNALING ON T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (T- 3 ALL): Perera Y et al. CO 004: In Silico DESIGN AND FUNCTIONAL CHARACTERIZATION OF A TGFβ1 MUTEIN, ANTAGONISTIC OF TGFβ SIGNALING, WITH ANTITUMOR AND IMMUNEMODULATORS 3 PROPERTIES: Corría Osorio J et al. CO 005: MOLECULAR MECHANISMS INVOLVED IN THE INHIBITION OF TUMOR CELLS PROLIFERATION EXPOSED TO ELEVATED CONCENTRATIONS OF EPIDERMAL GROWTH FACTOR 4 (EGF): Camacho H et al. CO 006: CONCENTRATION OF MMP-3 AND IL-6 IN PATIENTS WITH SEPSIS AND MULTIORGAN FAILURE: Ricarte Bratti JP et al. 4 CO 008: IMMUNOTRANS-ARTERIAL CHEMOEMBOLIZATION (ITACE) IN HEPATOCELLULAR CARCINOMA PATIENTS TREATED WITH ANTI-EGFR MAB NIMOTUZUMAB PLUS ADRIAMYCIN. 5 PHASE I CLINICAL TRIAL, FINAL RESULTS: Ramos-Suzarte M et al. CO 009: A NOVEL PEPTIDE SELECTED FROM AN ALA-SCANNING REGULATES THE ONCOGENIC ACTIVITY OF NFKB IN CANCER CELLS: Oliva B et al. 5 CO 010: NEOPLASTIC transformation of human mesenchymal stem cells CONCERTS IMmune-evasion and pro-iNflaMmatory programs IN THE ABSENCE OF IMMUNe-EDITION MEDIATED 6 PREASSURE: Miranda-Rodríguez A et al. CO 011: PRECLINICAL EVIDENCES OF P3 MAB IMMUNORESTORATION CAPACITY ON SUPPRESSED BALB/c MICE: Martínez D et al. 6 CO 012: PANUSIN, A NEW DEFENSIN-LIKE ANTIMICROBIAL PEPTIDE FROM THE HEMOCYTES OF SPINY LOBSTER Panulirus argus: Pacios-Michelena A et al. 7 CO 013: BIOMODULINA T: IMMUNOMODULATOR NATURAL PRODUCT OF THE LIFE´S QUALITY: Aznar García E et al. 7 Simposio de Ensayos Clínicos /: Symposium on Clinical Trials 8 CO 015: ETHICAL CONSIDERATIONS IN DEVELOPING COUNTRIES IN HIV VACCINE TRIALS: Ellis G. 8 CO 016: CANCER CLINICAL TRIALS: STATE OF THE ART AND THE CUBAN EXPERIENCE: Crombet-Ramos T. 8 CO 017: PHARMACODYNAMICS AND PHARMACOKINETICS OF TWO FORMULATIONS CONTAINING SYNERGISTIC PROPORTIONS OF INTERFERONS ALPHA-2B AND GAMMA IN HEALTHY 9 MALE VOLUNTEERS (SOFIA STUDY): García I et al. CO 019: SERUM LEVELS OF INFLAMMATORY MARKERS IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION DURING A 6 MONTH FOLLOW UP: Brizuela NY et al. 9 CO 020: SUBJECT: NATIONAL BIOETHICS NETWORK AND RESEARCH IN PERU - RENABIP: Socualaya P et al. 10 CO 021: CLINICAL TRIAL DESIGNS THAT CAN SPEED UP NEW DRUG DEVELOPMENT: López-Saura PA et al. 10 MR 001: CLINICAL TRIALS: PERSPECTIVE AND UPDATING: Pascual López MA et al. 11 CO 022: EFFICACY AND SAFETY OF RECOMBINANT STREPTOKINASE VERSUS HYDROCORTISONE ACETATE-BASED SUPPOSITORIES IN THE TREATMENT OF HEMORRHOIDAL DISEASE. 11 RANDOMIZED, CONTROLLED TRIAL (THERESA-4 Study): Hernández-Bernal F et al. CO 023: TRIMETAZIDINE INHIBITS THE RENAL FIBROSIS INDUCED BY CYCLOSPORIN A: De la Cruz Rodríguez L et al. 12 Taller de Métodos Alternativos (3Rs) en Farmacología, Toxicología y Enseñanza / Workshop on 3Rs Alternatives in Pharmacology, Toxicology and Teaching. 13 C 003: INTERNATIONAL VALIDATION AND REGULATORY ACCEPTANCE OF ALTERNATIVE METHODS: PROGRESSES AND PROSPECTS: Eskes C. 13 CO 024: ALTERNATIVE METHODS IN THE SAFETY EVALUATION OF COSMETIC: EUROPEAN SITUATION: Vinardell MP. 13 CO 025: PRINCIPLE OF REDUCTION AND THE VALIDITY AND EFFICIENCY OF ANIMAL ASSAYS: Rosenkranz A. 14 CO 026: ALTERNATIVE METHODS AND THE SAFETY ASSESSMENT OF HEALTH PRODUCTS: EXPERIENCE OF NATIONAL INSTITUTE OF QUALITY CONTROL IN HEALTH, BRAZIL: Fernandes 14 Delgado I et al. CO 027: PROPOSED METHODS AND ESPECIALLY STEM CELLS AS POTENTIAL REPLACEMENT METHODS TO STUDY HUMAN PATHOLOGIES: Bercovier H. 15 CO 028: BASIC ASPECTS OF THE TOXICOLOGICAL EVALUATION OF NANOMATERIALS: Vinardell MP et al. 15 Taller de Métodos Alternativos (3Rs) en Farmacología, Toxicología y Enseñanza / Workshop on 3Rs Alternatives in Pharmacology, Toxicology and Teaching. 16 CO 029: BEST PRACTICE AND ALTERNATIVES TO ANIMAL EXPERIMENTS IN EDUCATION: Jukes N. 16 CO 031: ALTERNATIVES TO THE USE OF ANIMALS IN VETERINARY MEDICINE EDUCATION: Torres M et al. 16 CO 032: SUPER-SELECTIVE OPHTHALMIC ARTERY CATHETERIZATION IN THE PIG AS A TRAINING MODEL WITH POSSIBLE IMPLICATIONS FOR RETINOBLASTOMA TREATMENT: Asprea 17 M et al. CO 033: USING VIDEOS AND PLASTINATED MURINE MODELS FOR TRAINING: Streber ML et al. 17 CO 034: DISSECTION OF THE VENTRAL NERVE CORD-DEEP ABDONIMAL FLEXOR MUSCLE SYSTEM OF THE FRESHWATER LOBSTER OF THE Cherax GENUS: AN IN SITU MODEL FOR 18 TEACHING PHARMACOLOGY: Islas V et al. http://jppres.com/jppres J Pharm Pharmacogn Res (2014) 2(Suppl. 1):sxi LATINFARMA 2013 Índice/Index Taller de Farmacoepidemiología / Workshop on Pharmacoepidemiology 19 C 004: THE DISCREET FASCINATION OF THE DRUGS: Pérez J. 19 CO 036: DRUG USE IN PREGNANT WOMEN: Viroga S et al. 19 CO 037: MEDICAL PRACTICE CONFIRMS CLINICAL TRIAL RESULTS OF THE USE OF INTRALESIONAL HUMAN RECOMBINANT EPIDERMAL GROWTH FACTOR IN ADVANCED DIABETIC 20 FOOT ULCERS: López-Saura PA et al. CO 038: FREQUENCY OF USE OF THE MONOCLONAL ANTIBODY RITUXIMAB ON THE NATIONAL CANCER INSTITUTE OF MEXICO: ONE YEAR EXPERIENCE: López-Gamboa M et al. 20 C 005: PHARMACOKINETIC CHANGES INDUCED BY SPINAL CORD INJURY: Castañeda G. 21 CO 039: RATIONAL USE OF MEDICINES IN PRIMARY HEALTH CARE: POLYPHARMACY IN PEOPLE AGED 60 YEARS AND OLDER: Ponce LN et al. 21 CO 040: EDUCATIVE INTERVENTION ON ESSENTIAL MEDICATIONS TO BE USED IN DISASTERS BY FAMILY DOCTORS IN ARROYO NARANJO MUNICIPALITY, IN 2012: López Aguilera AF et 22 al. CO 041: EFFECTIVENESS OF ANTIRETROVIRAL TREATMENT IN COLOMBIA: Machado-Alba JE et al. 22 CO 042: IMPACT OF AN ANTIBIOTIC POLICY ON ANTIMICROBIAL CONSUMPTION AT COMANDANTE MANUEL FAJARDO UNIVERSITY HOSPITAL, 2011: Morejón M et al. 23 CO 043: CLINICAL PHARMACIST PERFORMANCE IN MULTIPROFESSIONAL TEAM IN A TEACHING HOSPITAL: Amaral Pedroso L et al. 23 CO 044: LIPID-LOWERING THERAPY EFFECTIVENESS IN A SAMPLE OF COLOMBIAN PATIENTS: Machado-Alba JE et al. 24 CO 045: NSAID AND GASTROPROTECTIVE AGENTS PRESCRIPTION AT THE CLINICAL HOSPITAL “DR. MANUEL QUINTELA”: Cuñetti L et al. 24 Simposio de Farmacología del Dolor / Symposium on Pharmacology of Pain 25 C 006: BETWEEN HYPERTENSION AND PAIN: Henrique Ferreira S. 25 CO 046: MANGIFERIN FOR THE MANAGEMENT OF PAIN: ADVANTAGES OF ITS TRANSCIENT AND LONG TERM NEUROMODULATORY EFFECTS: Garrido BB et al. 25 CO 047: ANTINOCICEPTIVE ACTIVITY OF MANGIFERIN IN FORMALIN PAIN: Espinoza de los Monteros-Zuñiga A et al. 26 CO 048: ANTI-HYPERALGESIC EFFECT OF A NEUROPROTECTIVE COMPOUND IN ANIMAL MODELS OF PAIN: Castro M et al. 26 C 007: PHENOTYPIC MODIFICATIONS OF PRIMARY AFFERENT NEURONS INNERVATING OSTEOARTHRITIC JOINTS: Castro-Lopes JM et al. 27 C 008: THE RATIONALE OF ANALGESIS COMBINATIONS: Granizo E. 27 C 009: CARDIOVASCULAR RISK OF NONSTEROIDAL ANTI-INFLAMMATORY DRUG FREQUENTLY USED: Prozzi GR. 28 CO 051: OPIOIDS UPDATE IN 2013. PAIN FREE HOSPITALS, IMPORTANCE OF ITS DEVELOPMENT IN CUBA: Yera-Nadal JL.